اعلان هااااااااااااااام


Translate

EISAI RECEIVES SIX-MONTH PEDIATRIC EXCLUSIVITY FOR PROTON-PUMP INHIBITOR ACIPHEX® IN THE U.S. (Eisai Co Ltd)

Monday, December 10, 2012

WN.com - Health News
Latest headlines from WN Network
EISAI RECEIVES SIX-MONTH PEDIATRIC EXCLUSIVITY FOR PROTON-PUMP INHIBITOR ACIPHEX® IN THE U.S. (Eisai Co Ltd)
Dec 10th 2012, 07:25

(Source: Eisai Co Ltd) EISAI RECEIVES SIX-MONTH PEDIATRIC EXCLUSIVITY FOR PROTON-PUMP INHIBITOR ACIPHEX® IN THE U.S. Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that pediatric clinical data on proton-pump inhibitor AcipHex® (generic name: rabeprazole sodium, product name in Japan: Pariet®) submitted to the U.S. Food and Drug Administration (FDA) by U.S....
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 Responses to EISAI RECEIVES SIX-MONTH PEDIATRIC EXCLUSIVITY FOR PROTON-PUMP INHIBITOR ACIPHEX® IN THE U.S. (Eisai Co Ltd)

Post a Comment